Preclinical pharmacology and toxicology evaluation of an anti-CD52 monoclonal antibody produced by perfusion fermentation process

Anti-cluster of differentiation 52 (CD52) monoclonal antibody (mAb) has been employed in the treatment of chronic lymphoblastic leukemia and multiple sclerosis. Previously we developed a perfusion process to produce the biosimilar mAb named “Mab-TH.” A series of quality assessments was conducted in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yanchao, Zheng, Chen, Zhuang, Chao, Fu, Qiang, Qin, Jinyan, Zhang, Baohong, Bian, Yanling, Qi, Nianmin, Zhu, Jianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Fermentation, Cell Culture and Bioengineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788881/
https://www.ncbi.nlm.nih.gov/pubmed/34669957
http://dx.doi.org/10.1093/jimb/kuab078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788881/
https://www.ncbi.nlm.nih.gov/pubmed/34669957
http://dx.doi.org/10.1093/jimb/kuab078

Ejemplares similares